Shuiying HU  SITE

  • Molecules. 2021;26:5500. Endogenous Bbiomarkers for SLC transporter-mediated Drug-Drug Interaction evaluation. Li Y, Talebi Z, Chen X, Sparreboom A, Hu S. PubMed
  • Basic Clin Pharmacol Toxicol. 2021;In press. Contribution of membrane transporters to chemotherapy-induced cardiotoxicity. Uddin ME, Moseley A, Hu S, Sparreboom A. PubMed
  • Pharmaceutics. 2021;13:918. Imaging-based characterization of a Slco2b1(-/-) mouse model using [11C]Erlotinib and [99mTc]Mebrofenin as probe substrates. Marie S, Hernández-Lozano I, Breuil L, Truillet C, Hu S, Sparreboom A, Tournier N, Langer O. PubMed
  • Front Pharmacol. 2021;12:644342. Influence of YES1 Kinase and Tyrosine Phosphorylation on the activity of OCT1. Uddin ME, Garrison DA, Kim K, Jin Y, Eisenmann ED, Huang KM, Gibson AA, Hu Z, Sparreboom A, Hu S. PubMed
  • Clin Cancer Res. 2021;27:4301-4310. Regulation of OATP1B1 function by tyrosine kinase-mediated phosphorylation. Hayden E, Chen M, Pasquariello KZ, Gibson AA, Petti JJ, Shen S, Qu J, Ong SS, Chen T, Jin Y, Uddin ME, Huang KM, Paz A, Sparreboom A, Hu S, Sprowl JA. PubMed
  • Proc Natl Acad Sci U S A. 2021;118:e2020168118. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. PubMed
  • Rev Physiol Biochem Pharmacol. 2020;In press. Solute Carrier Transportome in chemotherapy-induced adverse drug reactions. Anderson JT, Huang KM, Lustberg MB, Sparreboom A, Hu S. PubMed
  • Clin Transl Sci. 2021;14:460-467. Role for drug transporters in chemotherapy-induced peripheral neuropathy. Stage TB, Hu S, Sparreboom A, Kroetz DL. PubMed
  • Clin Transl Sci. 2021;14:137-142. DNA methylation-based epigenetic repression of SLC22A4 promotes resistance to Cytarabine in Acute Myeloid Leukemia. Buelow DR, Anderson JT, Pounds SB, Shi L, Lamba JK, Hu S, Gibson AA, Goodwin EA, Sparreboom A, Baker SD. PubMed
  • Expert Opin Drug Metab Toxicol. 2020;16:493-506. Role of SLC transporters in toxicity induced by anticancer drugs. Huang KM, Uddin ME, DiGiacomo D, Lustberg MB, Hu S, Sparreboom A. PubMed
  • J Clin Invest. 2020;130:4601-4606. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson A, Li Y, Hong KW, DiGiacomo D, Xia SH, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg M, Cavaletti G, Pabla N, Hu S, Sparreboom A. PubMed
  • Expert Opin Drug Metab Toxicol. 2020;16:493-506. Role of SLC transporters in toxicity induced by anticancer drugs. Huang KM, Uddin ME, DiGiacomo D, Lustberg MB, Hu S, Sparreboom A. PubMed
  • Drug Metab Dispos. 2020;48:419-425. Role of Oatp2b1 in drug absorption and Drug-Drug Interactions. Chen M, Hu S, Li Y, Gibson AA, Fu Q, Baker SD, Sparreboom A. PubMed
  • Pharmacol Res Perspect. 2019;7:e00534. Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice. Anderson JT, Hu S, Fu Q, Baker SD, Sparreboom A. PubMed
  • CPT Pharmacometrics Syst Pharmacol. 2019;8:931-939. Predicting Paclitaxel disposition in humans with Whole-Body Physiologically-Based Pharmacokinetic Modeling. Fu Q, Sun X, Lustburg MB, Sparreboom A, Hu S. PubMed
  • Clin Pharmacol Ther. 2019;107:227-237. Sorafenib activity and disposition in liver cancer does not depend on Organic Cation Transporter 1. Chen M, Neul C, Schaeffeler E, Frisch F, Winter S, Schwab M, Koepsell H, Hu S, Laufer S, Baker SD, Sparreboom A, Nies AT. PubMed
  • Mater Sci Eng C Mater Biol Appl. 2019;102:113-123. Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy. Dwivedi P, Han S, Mangrio F, Fan R, Dwivedi M, Zhu Z, Huang F, Wu Q, Khatik R, Cohn DE, Si T, Hu S, Sparreboom A, Xu RX. PubMed
  • Clin Cancer Res. 2019;25:6295-6301. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. PubMed
  • Bio Protoc. 2018 Oct 20;8(20). pii: e3056. Murine pharmacokinetic studies. Leblanc AF, Huang KM, Uddin ME, Anderson JT, Chen M, Hu S. PubMed
  • J Pharm Biomed Anal. 2019;172:183-188. Development and validation of a UPLC-MS/MS analytical method for dofetilide in mouse plasma and urine, and its application to pharmacokinetic study. Uddin ME, Sun X, Huang KM, Hu S, Carnes CA, Sparreboom A, Fu Q. PubMed
  • Clin Transl Sci. 2019;12:400-407. Interaction between sex and Organic Anion-Transporting Polypeptide 1b2 on the harmacokinetics of Regorafenib and its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in mice. Fu Q, Chen M, Anderson JT, Sun X, Hu S, Sparreboom A, Baker SD. PubMed
  • Clin Pharmacol Ther. 2018;104:799-802. Strategies to reduce Solute Carrier-mediated toxicity. Hu S, Sprowl JA. PubMed
  • Pharmacogenomics. 2018;19:883-888. Drug transporters and anthracycline-induced cardiotoxicity. Huang KM, Hu S, Sparreboom A. PubMed
  • J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1090:43-51. Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. Fu Q, Chen M, Hu S, McElroy CA, Mathijssen RH, Sparreboom A, Baker SD. PubMed
  • J Clin Invest. 2018;128:816-825. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, Hong KW, Pioso MS, Chen M, Huang KM, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen RH, Reinbolt RE, Lustberg MB, Sucheston-Campbell LE, Cavaletti G, Sparreboom A, Hu S. PubMed
  • Clin Transl Sci. 2017;10:412-420. Identification of OAT1/OAT3 as contributors to Cisplatin toxicity. Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens J, Baker SD, Pabla N, Sparreboom A. PubMed
  • Clin Transl Sci. 2017;10:271-279. Influence of OATP1B1 function on the disposition of Sorafenib-β-D-Glucuronide. Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD. PubMed
  • Cancer Res. 2017;77:2102-2111. OCTN1 is a high-affinity carrier of nucleoside analogues. Drenberg CD, Gibson AA, Pounds SB, Shi L, Rhinehart DP, Li L, Hu S, Du G, Nies AT, Schwab M, Pabla N, Blum W, Gruber TA, Baker SD, Sparreboom A. PubMed
  • Nat Commun. 2016;7:10880. A phosphotyrosine switch regulates organic cation transporters. Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L5, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N. PubMed
  • Clin Transl Sci. 2016;9:51-9. ABCC4 is a determinant of Cytarabine-induced cytotoxicity and myelosuppression. Drenberg CD, Hu S, Li L, Buelow DR, Orwick SJ, Gibson AA, Schuetz JD, Sparreboom A, Baker SD. PubMed
  • Cancer Res. 2016;76:117-26. Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death. Zimmerman EI, Gibson AA, Hu S, Vasilyeva A, Orwick SJ, Du G, Mascara GP, Ong SS, Chen T, Vogel P, Inaba H, Maitland ML, Sparreboom A, Baker SD. PubMed
  • Clin Pharmacol Ther. 2016;99:651-60. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD. PubMed
  • Cancer Res. 2015;75:2729-36. Hepatocellular shuttling and recirculation of Sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b. Vasilyeva A, Durmus S, Li L, Wagenaar E, Hu S, Gibson AA, Panetta JC, Mani S, Sparreboom A, Baker SD, Schinkel AH. PubMed
  • Proc Natl Acad Sci U S A. 2015;112:5231-6. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Pabla N, Gibson AA, Buege M, Ong SS, Li L, Hu S, Du G, Sprowl JA, Vasilyeva A, Janke LJ, Schlatter E, Chen T, Ciarimboli G, Sparreboom A. PubMed
  • Cancer Res. 2014;74:3137-45. Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Nieuweboer AJ, Hu S, Gui C, Hagenbuch B, Ghobadi Moghaddam-Helmantel IM, Gibson AA, de Bruijn P, Mathijssen RH, Sparreboom A. PubMed
  • Clin Cancer Res. 2014;20:985-94. Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Nies AT, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M, Pott C, Hofmann U, Volk C, Hu S, Baker SD, Sparreboom A, Ruth P, Koepsell H, Schwab M. PubMed
  • Clin Pharmacol Ther. 2013;94:585-92. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Sprowl JA, van Doorn L, Hu S, van Gerven L, de Bruijn P, Li L, Gibson AA, Mathijssen RH, Sparreboom A. PubMed
  • Clin Cancer Res. 2013;19:4359-4370. Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. Furmanski BD, Hu S, Fujita KI, Li L, Gibson AA, Janke LJ, Williams RT, Schuetz JD, Sparreboom A, Baker SD. PubMed
  • Mol Cancer Ther. 2013;12:1537-44. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A. PubMed
  • Clin Cancer Res. 2013;19:1458-66. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A, Baker SD. PubMed
  • Clin Pharmacol Ther. 2012;92:642-50. OATP1B1 polymorphism as a determinant of erythromycin disposition. Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, Hu S, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A. PubMed
  • Clin Cancer Res. 2012;18:4433-40. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A. PubMed
  • Mol Cancer Ther. 2012;11:921-9. Inhibition of OCTN2-mediated transport of carnitine by etoposide. Hu C, Lancaster CS, Zuo Z, Hu S, Chen Z, Rubnitz JE, Baker SD, Sparreboom A. PubMed
  • Clin Cancer Res. 2009;15:6062-9. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD. PubMed
  • Clin Pharmacol Ther. 2009;85:155-63. Pharmacogenetic pathway analysis of docetaxel elimination. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. PubMed
  • Clin Cancer Res. 2008;14:3141-8. Interaction of imatinib with human organic ion carriers. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A. PubMed

PubMed

Columbus, United States

HuShuiying.jpg

Last update: October 2021